Quanticel quantified

Versant Ventures has spurned the traditional syndicate route for cancer play Quanticel Pharmaceuticals Inc. In two years, the VC has formed the company and taken it to a partnership and potential exit.

Celgene Corp. (NASDAQ:CELG) has committed $45 million as part of a three-and-a-half year deal in which Quanticel will perform single-cell genomic analysis of patient tumor samples and identify predictive biomarkers for Celgene's products...